Biogen Announces FDA’s Three-Month Extension of Review Period for the New Drug Application for Tofersen

Biogen Inc. announced that the FDA has extended the review period of the new drug application for tofersen by three months. Tofersen is an investigational treatment for superoxide dismutase amyotrophic lateral sclerosis.